AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11915063 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic-only axillary block, and IM buprenorphine 0.3 mg
Number of subjects: 60
Study 11915063 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic-only axillary block and IM saline
Number of subjects: 60
Study 9690311 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy (exact regimen not specified)
Number of subjects: 0
Study 9690311 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher radiation doses, conformal radiotherapy, altered fractionation schedules, and possibly adjuvant surgery
Number of subjects: 0
Study 9690311 — intervention group
Group type: EXPERIMENTAL
Intervention: New combined modality strategies and new drugs
Number of subjects: 0
Study 7621761 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 199
Study 7621761 — intervention group
Group type: COMPARATOR
Intervention: Evacuation by curettage (E by C)
Number of subjects: 199
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine gel
Number of subjects: 172
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Acetylcholine chloride
Number of subjects: 172
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% Carbachol
Number of subjects: 172
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% Carbachol
Number of subjects: 172
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 172
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% Carbachol (full-strength)
Number of subjects: 172
Study 2361193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% Carbachol (half-strength)
Number of subjects: 172
Study 2361193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 6751839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance training program
Number of subjects: 28
Study 6751839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 6751839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 31100155 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment using the sutured intravitreal fluocinolone acetonide implant
Number of subjects: 0
Study 31100155 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment consisting of oral steroids and conventional steroid‐sparing immunosuppression
Number of subjects: 0
Study 28371205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg once/day
Number of subjects: 211
Study 28371205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 25977128 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR checklist users
Number of subjects: 60
Study 23357717 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline energy loss index (ELI)
Number of subjects: 1563
Study 21344271 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (6-week laboratory-based program)
Number of subjects: 58
Study 19057513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 208
Study 19057513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 208
Study 19057513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 25 mg
Number of subjects: 208
Study 19057513 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 208
Study 19057513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 20535927 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) combined with chemotherapy (FOLFOX protocol)
Number of subjects: 40
Study 20535927 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (FOLFOX protocol) alone
Number of subjects: 40
Study 15574127 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril alone
Number of subjects: 64
Study 15574127 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil alone
Number of subjects: 64
Study 15574127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril and sildenafil
Number of subjects: 64
Study 15574127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12169969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph II stereometric parameters
Number of subjects: 50
Study 12169969 — intervention group
Group type: EXPERIMENTAL
Intervention: Moorfields regression analysis
Number of subjects: 50
Study 12169969 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression analysis software
Number of subjects: 50
Study 15539283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) 1 g/14 kg body weight/day for 4 weeks
Number of subjects: 6
Study 15539283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 6
Study 7786833 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg daily
Number of subjects: 40
Study 7786833 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg daily
Number of subjects: 40
Study 7786833 — intervention group
Group type: COMPARATOR
Intervention: celiprolol
Number of subjects: 40
Study 7786833 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 40
Study 2361721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 2361721 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgin
Number of subjects: 0
Study 2361721 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 2361721 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 154372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholebrin
Number of subjects: 100
Study 154372 — intervention group
Group type: COMPARATOR
Intervention: Telepaque
Number of subjects: 100
Study 154372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholebrin and Telepaque
Number of subjects: 100
Study 12086366 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (58.2 x 10(7) CFUs)
Number of subjects: 43
Study 12086366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30047538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 200
Study 30047538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trimetazidine)
Number of subjects: 200
Study 27442052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarming (forced-air warming during induction of anesthesia)
Number of subjects: 40
Study 27442052 — intervention group
Group type: COMPARATOR
Intervention: Control (no prewarming)
Number of subjects: 40
Study 24332141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4323
Study 24332141 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 4323
Study 22150065 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 W/100 Hz
Number of subjects: 72
Study 22150065 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 W/100 Hz
Number of subjects: 72
Study 22150065 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (control)
Number of subjects: 72
Study 20938912 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir (800 mg three times daily without ritonavir)
Number of subjects: 40
Study 20938912 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir (400 mg twice daily with 200 mg ritonavir twice daily)
Number of subjects: 40
Study 20938912 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir (with or without ritonavir) in combination with PEG‐IFN‐α‐2b
Number of subjects: 40
Study 20938912 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (PEG‐IFN‐α‐2b and ribavirin treatment)
Number of subjects: 40
Study 18574771 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) mobilization, PBMC collection by leukapheresis and PBMC transplant therapy
Number of subjects: 40
Study 18574771 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-colony-stimulating factor (G-CSF) mobilization for 4 days
Number of subjects: 40
Study 16105609 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 19
Study 16105609 — intervention group
Group type: COMPARATOR
Intervention: Dapiprazole
Number of subjects: 19
Study 12046816 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol monotherapy
Number of subjects: 24
Study 12046816 — intervention group
Group type: COMPARATOR
Intervention: Untreated control lesions
Number of subjects: 24
Study 10412920 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 treatment (intravenous and intracoronary)
Number of subjects: 24
Study 10412920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CoQ10 treatment)
Number of subjects: 24
Study 8585104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 25 mg sematilide HCl
Number of subjects: 0
Study 8585104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 25 mg sematilide HCl
Number of subjects: 0
Study 2180144 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonyl iron (100 mg orally at bedtime for 56 days)
Number of subjects: 99
Study 2180144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 2180144 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonyl iron
Number of subjects: 99
Study 2180144 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening
Number of subjects: 99
Study 91432 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgicopathologic staging system based on serum alphafetoprotein and human chorionic gonadotropin determination before and/or after orchiectomy and lymphadenectomy.
Number of subjects: 0
Study 91432 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging system using lymphangiogram, iv pyelogram, and inferior venacavogram.
Number of subjects: 0
Study 91432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with or without cytoreductive surgery.
Number of subjects: 0
Study 31530556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zostavax (live-attenuated herpes zoster vaccine)
Number of subjects: 90
Study 31530556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29644582 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 200 mg per day for 5 weeks
Number of subjects: 8
Study 29644582 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 8
Study 26997495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Test of Cigarette Dependence (FTCD) score
Number of subjects: 784
Study 26997495 — intervention group
Group type: EXPERIMENTAL
Intervention: Expired carbon monoxide (CO) level
Number of subjects: 784
Study 26997495 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked per day
Number of subjects: 784
Study 26997495 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of urges to smoke
Number of subjects: 784
Study 25128327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary-ESA (SE)
Number of subjects: 36
Study 25128327 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-placebo (TP)
Number of subjects: 36
Study 25128327 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-ESA (TE)
Number of subjects: 36
Study 25128327 — intervention group
Group type: COMPARATOR
Intervention: Sedentary-placebo (SP)
Number of subjects: 36
Study 22772319 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week)
Number of subjects: 0
Study 22772319 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (≤ 3 g/day)
Number of subjects: 0
Study 20134284 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational message pamphlet emphasizing learning CPR and AED use to save someone they love and the 3-minute window for response time
Number of subjects: 220
Study 20134284 — intervention group
Group type: COMPARATOR
Intervention: Identical pamphlet without the 2 motivational statements (comparison group)
Number of subjects: 220
Study 20134284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 220
Study 17289895 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin and vinorelbine
Number of subjects: 265
Study 17289895 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 265
Study 16128935 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (group A - 15 patients)
Number of subjects: 44
Study 16128935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B - 15 patients)
Number of subjects: 44
Study 16128935 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with documented GERD
Number of subjects: 44
Study 16128935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 44
Study 11471577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to the most affected knee only (Group A)
Number of subjects: 44
Study 11471577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to both knees (Group B)
Number of subjects: 44
Study 9492129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine, epinephrine, and tetracaine (LET) solution
Number of subjects: 60
Study 9492129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water) solution
Number of subjects: 60
Study 8060627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial brachial plexus block with 60 to 70 ml of local anesthetic solution
Number of subjects: 346
Study 8060627 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience in performing the block
Number of subjects: 346
Study 8060627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial brachial plexus block
Number of subjects: 346
Study 2493800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxapram (300 mg and 600 mg)
Number of subjects: 0
Study 2493800 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.12 mg kg‐1 i.m.)
Number of subjects: 0
Study 2493800 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study 2493800 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram alone (300 mg and 600 mg)
Number of subjects: 0
Study 30653519 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire for epilepsy
Number of subjects: 4768
Study 30653519 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire for WSCH
Number of subjects: 4768
Study 30653519 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted prevalence estimates for epilepsy and WSCH
Number of subjects: 4768
Study 28078435 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 78
Study 28078435 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 78
Study 25960104 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis group (n = 40) stopped brushing and flossing, used only fluoride anti‐cavity mouth rinse for 21 days.
Number of subjects: 80
Study 25960104 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40) conducted an oral hygiene regimen: brushing twice daily with sodium fluoride dentifrice, flossing twice daily, and mouth rinsing with anti‐cavity fluoride rinse once daily.
Number of subjects: 80
Study 23046948 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-nut cream (CC)
Number of subjects: 12
Study 23046948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenol extract in free form (FPC)
Number of subjects: 12
Study 23046948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenol extract encapsulated (EPC)
Number of subjects: 12
Study 23046948 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC
Number of subjects: 12
Study 23046948 — intervention group
Group type: EXPERIMENTAL
Intervention: FPC
Number of subjects: 12
Study 23046948 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 12
Study 21549529 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 30
Study 19346370 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pafuramidine eight days before challenge
Number of subjects: 16
Study 19346370 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pafuramidine the day before challenge
Number of subjects: 16
Study 19346370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17119522 — intervention group
Group type: EXPERIMENTAL
Intervention: ExCLA (exercise + CLA)
Number of subjects: 44
Study 17119522 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (CLA supplementation only)
Number of subjects: 44
Study 17119522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex (exercise only)
Number of subjects: 44
Study 17119522 — intervention group
Group type: COMPARATOR
Intervention: C (control group)
Number of subjects: 44
Study 15123336 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified medium chain triglycerides (MCTs)
Number of subjects: 20
Study 15123336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg over 3 days)
Number of subjects: 66
Study 12463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine
Number of subjects: 66
Study 12463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (in vitro)
Number of subjects: 66
Study 12463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (in vitro)
Number of subjects: 66
Study 12463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (in vitro)
Number of subjects: 66
Study 12463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (in vitro)
Number of subjects: 66
Study 9022434 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice doctors
Number of subjects: 2152
Study 9022434 — intervention group
Group type: COMPARATOR
Intervention: Deputising doctors
Number of subjects: 2152
Study 8160983 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 75
Study 8160983 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 75
Study 8160983 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil increments
Number of subjects: 75
Study 3128465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (200 micrograms/min)
Number of subjects: 12
Study 3128465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.4 IU/min)
Number of subjects: 12
Study 3128465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vasopressin and nitroglycerin
Number of subjects: 12
Study 31581929 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (200 mmHg pressure, twice daily for 10-14 days)
Number of subjects: 1800
Study 31581929 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based therapy (control group)
Number of subjects: 1800
Study 30303980 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented 40mcg HBV dose schedule
Number of subjects: 0
Study 30303980 — intervention group
Group type: COMPARATOR
Intervention: Seasonal influenza vaccination (Fluvax)
Number of subjects: 0
Study 26545149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D, N=25) at 0.5 µg/kg over 10 minutes, followed by an infusion at 0.5 µg/kg/h until the end of surgery
Number of subjects: 50
Study 26545149 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group S, N=25)
Number of subjects: 50
Study 26253520 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) with 220 g of lean red meat (raw weight) divided into two 80 g servings on training days
Number of subjects: 152
Study 26253520 — intervention group
Group type: COMPARATOR
Intervention: Control PRT with ≥1 serving (1/2 cup) of rice and/or pasta or 1 medium potato on training days
Number of subjects: 152
Study 26253520 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) with lean red meat
Number of subjects: 152
Study 26253520 — intervention group
Group type: COMPARATOR
Intervention: Control PRT
Number of subjects: 152
Study 23866774 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC)
Number of subjects: 300
Study 23866774 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 300
Study 21924404 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy, average of 4.1 sessions
Number of subjects: 19
Study 21924404 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 18563311 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol (5 mg/day)
Number of subjects: 32
Study 18563311 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 mg/day)
Number of subjects: 32
Study 16317550 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary sphincter-cutting procedures (fistulotomy and fistulectomy)
Number of subjects: 405
Study 16317550 — intervention group
Group type: COMPARATOR
Intervention: Drainage alone
Number of subjects: 405
Study 12142198 — intervention group
Group type: EXPERIMENTAL
Intervention: Zipper technique
Number of subjects: 300
Study 12142198 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous suture technique
Number of subjects: 300
Study 10211538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 and 500 microg twice daily
Number of subjects: 0
Study 10211538 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 300 and 500 microg twice daily
Number of subjects: 0
Study 10211538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg every morning
Number of subjects: 0
Study 10211538 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg twice daily
Number of subjects: 0
Study 10211538 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 500 microg twice daily
Number of subjects: 0
Study 10211538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8687088 — intervention group
Group type: EXPERIMENTAL
Intervention: AO/ASIF implants
Number of subjects: 69